Multidrug resistant acinetobacter.
Multidrug resistant acinetobacter.
复制标题
DOI：
10.4103/0974-777x.68538
复制
发表时间：
2010-09
影响因子：
1.6
通讯作者：
Singh N
中科院分区：
文献类型：
--
作者：
Manchanda V;Sanchaita S;Singh N
对大多数可用的抗微生物剂具有抗性的不动杆菌属物种的出现和传播是一个非常令人关注的领域。它现在经常与医疗保健相关的感染有关。在PUBMED、Google Scholar和科克伦图书馆检索文献，使用术语“不动杆菌耐药、多药耐药（MDR）、抗菌治疗、爆发、粘菌素、替加环素、AmpC酶和碳青霉烯酶（各种组合）”。MDR、广泛耐药（XDR）和泛耐药（PDR）等术语在已发表的文献中使用，定义不同，导致各种研究数据的相关性混淆。在这篇综述中，讨论了不动杆菌属的各种耐药机制。该综述还探讨了目前的治疗选择，包括可用于治疗成人和儿童耐药不动杆菌属感染的联合疗法。迫切需要执行感染控制措施和抗菌药物管理计划，以防止这些耐药不动杆菌物种的进一步传播，并推迟细菌耐药性增强的出现。
Emergence and spread of Acinetobacter species, resistant to most of the available antimicrobial agents, is an area of great concern. It is now being frequently associated with healthcare associated infections. Literature was searched at PUBMED, Google Scholar, and Cochrane Library, using the terms ‘Acinetobacter Resistance, multidrug resistant (MDR), Antimicrobial Therapy, Outbreak, Colistin, Tigecycline, AmpC enzymes, and carbapenemases in various combinations. The terms such as MDR, Extensively Drug Resistant (XDR), and Pan Drug Resistant (PDR) have been used in published literature with varied definitions, leading to confusion in the correlation of data from various studies. In this review various mechanisms of resistance in the Acinetobacter species have been discussed. The review also probes upon the current therapeutic options, including combination therapies available to treat infections due to resistant Acinetobacter species in adults as well as children. There is an urgent need to enforce infection control measures and antimicrobial stewardship programs to prevent the further spread of these resistant Acinetobacter species and to delay the emergence of increased resistance in the bacteria.